Interstitial Lung Disease Clinical Trial
Official title:
Enhancing Physical Activity in Patients With Interstitial Lung Disease: an Exploratory Randomized Controlled Trial
NCT number | NCT04138173 |
Other study ID # | S62505 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 14, 2020 |
Est. completion date | January 6, 2022 |
Verified date | March 2022 |
Source | KU Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The level of physical activity (PA) has been shown to be an important predictor for morbidity and mortality in patients with chronic respiratory diseases such as COPD and more recently Idiopathic Pulmonary Fibrosis. Physical inactivity is a common feature of patients with chronic respiratory diseases. Whereas pulmonary rehabilitation is known to result in benefits in exercise capacity, symptoms and quality of life, these gains will not automatically translate into increases in physical activity. Therefore, the present study aims to investigate the effect of a physical activity coaching program on the physical activity level of patients with interstitial lung disease.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 6, 2022 |
Est. primary completion date | January 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Stable patients, older than 18 year, with a diagnosis of interstitial lung disease 2. Understand and able to work with a smartphone application, as judged by the investigator 3. On stable pharmacotherapy 4. DLCO =30%predicted Exclusion Criteria: 1. On the waiting list for a lung transplantation 2. Life expectancy below 3 months 3. Respiratory tract infection or an exacerbation or change in maintenance medication within 4 weeks before study enrolment 4. Extra pulmonary impairments, unrelated to the underlying lung disease, interfering with physical activity |
Country | Name | City | State |
---|---|---|---|
Belgium | KULeuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
KU Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Physical activity from a patient's perspective (Exploratory endpoint) | The c-PPAC, a 12-item questionnaire assessing physical activity from a patient's perspective reflecting the past 7 days will be collected. The questionnaire investigates the amount of and difficulty with physical activity as perceived by the patient. The 2 domain scores (i.e. amount and difficult) as well as the total score will be retrieved as outcomes. | 12 weeks | |
Other | Time to first hospital admission | For explanatory purposes, time to first hospital admissions will be collected in these patients in the 2 years following on the present study. | 2 year | |
Other | Transplantation free survival | For explanatory purposes, transplantation free survival status will be collected in these patients in the 2 years following on the present study. | 2 year | |
Primary | Daily number of steps at 12 weeks | Change in weekly mean step count 12 weeks post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer (Dynaport Movemonitor) validated for use in in chronic respiratory disease. Data obtained on days with more than 8 hours of wearing time will be used for further analysis. A measurement will be considered valid when having more than four valid days. | 12 weeks | |
Secondary | Time spent in at least moderate intense activity | Change in daily time spent in at least moderate intense activity 12 weeks post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease. Data obtained on days with more than 8 hours of wearing time will be used for further analysis. | 12 weeks | |
Secondary | Mean walking time per day | Change in mean daily walking time 12 weeks post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease. Data obtained on days with more than 8 hours of wearing time will be used for further analysis. | 12 weeks | |
Secondary | Movement intensity | Change in mean movement intensity 12 weeks post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease. Data obtained on days with more than 8 hours of wearing time will be used for further analysis. | 12 weeks | |
Secondary | Activity bout duration | Change in mean duration of an activity bout 12 weeks post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease. Data obtained on days with more than 8 hours of wearing time will be used for further analysis. | 12 weeks | |
Secondary | Exercise capacity | Change in six-minutes walk distance 12 weeks post randomization in the intervention group as compared to the control group. The six-minute walking test will be performed with standardized encouragement to assess patients' functional exercise capacity. The best of two measurements will be used. | 12 weeks | |
Secondary | Maximal voluntary isometric quadriceps force | Change in isometric quadriceps force 12 weeks post randomization in the intervention group as compared to the control group. The quadriceps isometric strength will be evaluated by a maximal voluntary contraction using the Biodex, a computerized dynamometer. Patients will be seated with a 90° hip and 60° knee flexion. The best of 3 measurements will be taken into analysis as the maximal force capacity of the lower limb. | 12 weeks | |
Secondary | Health status | Health status will be measured by the The King's Brief Interstitial Lung disease (K-BILD) questionnaire. The K-BILD questionnaire is a valid self-completed health status measure for patients with interstitial lung disease consisting of 15 items that measures health status in 3 domains (Psychological, Breathlessness and activity and chest symptoms) and a total score. | 12 weeks | |
Secondary | Symptoms of anxiety and depression | Symptoms of anxiety and depression will be measured by the Hospital Anxiety and Depression Scale (HADs). The HADs is a generic screening measure of symptoms of anxiety and depression. The HADS is a 14 item measure comprising 7 anxiety items and 7 depression items from which separate anxiety and depression sub-scale scores are calculated. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Recruiting |
NCT05417776 -
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
|
Phase 2 | |
Not yet recruiting |
NCT04089826 -
Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
|
||
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
Completed |
NCT00362739 -
Blood Collection From Individuals With Lung Disease for Genetic Studies
|
N/A | |
Recruiting |
NCT06133998 -
Effects of Incentive Spirometry With and Without Aerobic Exercises in Interstitial Lung Disease
|
N/A | |
Active, not recruiting |
NCT03485378 -
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease
|
N/A | |
Recruiting |
NCT04098094 -
Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
|
||
Recruiting |
NCT03400839 -
Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
|
||
Terminated |
NCT02633293 -
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Active, not recruiting |
NCT05068869 -
Digital Outpatient Services
|
N/A | |
Active, not recruiting |
NCT03727568 -
Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases
|
N/A | |
Recruiting |
NCT06046547 -
Integrating Palliative Care Education in Pulmonary Rehabilitation
|
N/A | |
Completed |
NCT04946708 -
Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients
|
N/A | |
Recruiting |
NCT04139356 -
The Effect of Spontaneous Respiration on Pulse-oximetry Measurements
|
N/A | |
Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03295279 -
WTC Chest CT Imaging Archive
|